If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exercise of Warrants and Issue of Equity

2 May 2017 15:10

RNS Number : 9382D
Motif Bio PLC
02 May 2017
 

 

 

 

May 2, 2017 

 

 

Exercise of Warrants

 

 

Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics announces that it has received notification from warrant holders to exercise warrants over 16,344 ADSs representing 326,880 ordinary shares of 1p each ("Ordinary Shares") in the Company at an exercise price of $8.03 per ADS for total consideration of $131,242.32.

 

Application has been made for the 326,880 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 5 May 2017. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Following Admission, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 196,212,108 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

 

For further information please contact:

 

 

Motif Bio plc

info@motifbio.com

Graham Lumsden (Chief Executive Officer)

Robert Dickey IV (Chief Financial Officer)

Peel Hunt LLP (NOMAD & BROKER)

+ 44 (0)20 7418 8900

Dr Christopher Golden

Oliver Jackson

Northland Capital Partners Limited (BROKER)

+44 (0)203 861 6625

Patrick Claridge/ David Hignell

John Howes/ Rob Rees (Broking)

Walbrook PR Ltd. (FINANCIAL PR & IR)

+44 (0) 20 7933 8780 or motifbio@walbrookpr.com

Paul McManus

Mob: +44 (0)7980 541 893

Mike Wort

Mob: +44 (0)7900 608 002

MC Services AG (EUROPEAN IR)

+49 (0)89 210 2280

Raimund Gabriel

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSSWFLEFWSESI
Date   Source Headline
8th Jun 20172:32 pmRNSHolding(s) in Company
5th Jun 20176:20 pmRNSPublication of Shareholder Circular
2nd Jun 20174:36 pmRNSResult of Placing
2nd Jun 20177:00 amRNSProposed Placing
23rd May 20174:40 pmRNSSecond Price Monitoring Extn
23rd May 20174:35 pmRNSPrice Monitoring Extension
18th May 20177:00 amRNSPublication of UK Annual Report and Accounts
10th May 20177:00 amRNSAppointments to Scientific Advisory Board
5th May 20177:00 amRNSDirectorate Change
2nd May 20173:10 pmRNSExercise of Warrants and Issue of Equity
2nd May 20177:00 amRNSAnnual Financial Report
28th Apr 201712:00 pmRNSChange of Adviser
24th Apr 20177:00 amRNSNotification of change in holding of shareholder
18th Apr 20177:00 amRNSPositive Data Readout for Iclaprim Phase 3 Trial
12th Apr 20173:06 pmRNSHolding(s) in Company
12th Apr 20173:01 pmRNSHolding(s) in Company
31st Mar 20174:15 pmRNSChange of Registered Office
8th Feb 20172:57 pmRNSInvestor Presentation
8th Feb 20177:00 amRNSDirector/PDMR Shareholding
7th Feb 20177:02 amRNSDirector/PDMR Shareholding
31st Jan 20173:36 pmRNSHardman Research: Further de-risking of iclaprim
31st Jan 20177:00 amRNSClinical trial finishes patient treatment phase
27th Jan 20176:13 pmRNSHolding(s) in Company
18th Jan 20177:05 amRNSDirector/PDMR Shareholding
18th Jan 20177:00 amRNSAppointment of Chief Financial Officer
9th Jan 20175:28 pmRNSIssue of Equity
3rd Jan 201712:31 pmRNSHolding(s) in Company
30th Dec 20163:09 pmRNSHolding(s) in Company
30th Dec 20162:38 pmRNSHolding(s) in Company
21st Dec 20165:50 pmRNSConversion of CPNs, PDMR Dealing & TVR
21st Dec 20164:17 pmRNSIssue of Equity & Total Voting Rights
21st Dec 20163:05 pmRNSResult of GM
19th Dec 20165:58 pmRNSHolding(s) in Company
8th Dec 20167:45 amRNSHolding(s) in Company
5th Dec 20167:00 amRNSPublication of circular and notice of GM
1st Dec 20165:27 pmRNSIssue of Equity
25th Nov 201611:32 amRNSHolding(s) in Company
24th Nov 20161:36 pmRNSHolding(s) in Company
23rd Nov 20165:12 pmRNSHolding(s) in Company
23rd Nov 20164:56 pmRNSClosing of public offer
18th Nov 201612:51 pmRNSConfirms successful European placing
18th Nov 20167:16 amRNSUS Pricing and European Placing to raise US$25m
4th Nov 20161:34 pmRNSHolding(s) in Company
4th Nov 20161:20 pmRNSHolding(s) in Company
31st Oct 20167:00 amRNSUpdate on US Public Offering
31st Oct 20167:00 amRNSNew Data on Iclaprim
31st Oct 20167:00 amRNSData Confirming Standard Clinical Trial Dosage
16th Sep 20164:40 pmRNSSecond Price Monitoring Extn
16th Sep 20164:35 pmRNSPrice Monitoring Extension
15th Sep 20167:00 amRNSPosters presented at IDWeek New Orleans

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.